News | March 05, 2009

Closure of Patent Foramen Ovale May Benefit Migraine Sufferers

March 5, 2009 - Reducing the frequency and severity of disabling migraines is crucial for quality of life and a new study, published in the February 2009 issue of JACC: Cardiovascular Interventions, finds significant improvement of migraines following catheter-based closure of patent foramen ovale (PFO).

These findings confirm those of previous observational studies, which consistently show that when a PFO is closed - whether it’s following a stroke or decompression illness - migraine also tends to improve in the majority of cases (approximately 75 percent). However, the present study was the first to enroll patients with severe migraine, a large PFO and no history of stroke or transient ischemic attacks, but with silent brain lesions on magnetic resonance imaging.

“The study suggests closure of a large PFO may improve migraine in patients with subclinical brain lesions, as well as those with prior stroke,” said Carlo Vigna, M.D., of Casa Sollievo della Sofferenza IRCCS Hospital, San Giovanni Rotondo, Italy. “In the past, the beneficial effect on migraine was occasionally seen after PFO closure was performed for other reasons, for example, unexplained stroke. Conversely, the recently published MIST trial did not show significant improvement of symptoms in ‘pure migraneurs’ in the absence of symptomatic or subclinical cerebral ischemia. As compared with these two extremes, we enrolled patients with an intermediate subset of characteristics.”

Patients were divided into either the closure (n=53) or control (n=29) group based on their consent to undergo percutaneous PFO closure, and prospectively examined for six months. Compared with the medically treated control group, closure of a PFO resulted in greater numbers of patients who had cessation of migraine attacks, cessation of disabling attacks and more than 50 percent reduction in migraine attacks.

While this may be good news for certain migraine sufferers, researchers say a larger randomized trial focusing on this patient population is needed. In addition, the relationship between PFO and migraine must be further examined and understood.

“We don’t really know what’s going on. A stroke could be caused if a blood clot passes across a PFO and travels to the brain, but with migraine we don’t yet know what the trigger substance is that crosses the shunt,” said Dr. Peter Wilmshurst, Royal Shrewsbury Hospital, U.K. “Not everyone with migraine has a PFO, and not everyone with a PFO has migraine; there are other causes that we don’t yet understand.”

Research suggests people with migraine also have a higher prevalence of right-to-left shunts on contrast echocardiograms, which are, by and large, due to PFO - something everyone has while in the womb to divert blood away from the lungs. However, for one in four people, a hole remains after birth.

For more information: http://interventions.onlinejacc.org


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now